Open-label, Monocentric, Phase II, Investigator-initiated Clinical Trial on Unbiased Characterization of Immunological Parameters in Interleukin-2-treated Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms Charact-IL-2
- 31 Aug 2018 Biomarkers information updated
- 01 May 2018 Planned End Date changed from 31 Aug 2019 to 31 Mar 2020.
- 01 May 2018 Planned primary completion date changed from 30 Jun 2019 to 30 Dec 2019.